Current Recommendations for Coronary Artery Calcium Scoring
Coronary artery calcium (CAC) scoring is recommended for asymptomatic adults aged 40-75 years with borderline (5-7.5%) or intermediate (7.5-20%) 10-year ASCVD risk when treatment decisions remain uncertain after initial risk assessment. 1
Who Should Get CAC Scoring
Primary Candidates
- Asymptomatic adults aged 40-75 years with intermediate 10-year ASCVD risk (7.5-20%) 1
- Borderline risk patients (5-7.5%) when risk-enhancing factors are present and treatment decisions are unclear 1
- Selected low-risk patients with:
- Strong family history of premature coronary heart disease
- Diabetes mellitus patients aged 40-60 years (Type 1 DM <35 years, Type 2 DM <50 years with disease duration <10 years and no other risk factors) 1
Risk-Enhancing Factors That Support CAC Use
When present in borderline or intermediate-risk patients, these factors warrant consideration of CAC scoring 1:
- Family history of premature ASCVD
- Persistently elevated LDL-C ≥160 mg/dL or triglycerides ≥175 mg/dL
- Chronic kidney disease
- Metabolic syndrome
- Women-specific conditions (preeclampsia, premature menopause)
- Inflammatory diseases (rheumatoid arthritis, psoriasis, HIV)
- High-risk ethnicity (South Asian origin)
- Elevated hs-CRP ≥2.0 mg/L or Lp(a) >50 mg/dL in selected individuals
Treatment Thresholds Based on CAC Score
CAC = 0 (Zero Score)
- Downgrade risk and withhold statin therapy 1
- Exception: Consider statin if diabetes, family history of premature CHD, or active smoking present 1
- 10-year event rate: 1.5-3.0% 2
- Repeat CAC in 3-7 years if risk factors persist 1, 2
CAC = 1-99
- Favors statin therapy, especially after age 55 1
- Modest risk reclassification upward 2
- Consider repeating CAC in 3-5 years if treatment deferred (unless active smoker, diabetes, chronic inflammatory conditions, or family history of premature CAD) 2
CAC ≥ 100 or ≥75th Percentile for Age/Sex/Race
- Initiate statin therapy 1
- Event rate ≥20 events per 1000 person-years, approximating secondary prevention population 2
- SCCT specialty guideline: High-intensity statin + aspirin 81 mg 1
CAC ≥ 400
Who Should NOT Get CAC Scoring
Do not perform CAC scoring in: 2
- Symptomatic patients (chest pain, dyspnea) - CAC = 0 does not exclude obstructive CAD; 19% of symptomatic patients with CAC = 0 had ≥50% stenosis 2
- Known coronary artery disease
- High-risk patients already requiring statin therapy (≥20% 10-year risk)
- Very low-risk patients (<5% 10-year risk) without risk-enhancing factors
- Patients unwilling to alter therapy based on results 2
Clinical Decision Algorithm
Step 1: Calculate 10-Year ASCVD Risk
Use ASCVD Pooled Cohort Equation or MESA calculator for ages 40-75 years 2
Step 2: Risk Stratification
- Low (<5%): No CAC unless strong family history or other risk-enhancing factors 1
- Borderline (5-7.5%): Consider CAC if risk-enhancing factors present and treatment uncertain 1
- Intermediate (7.5-20%): CAC recommended when treatment decision unclear 1
- High (≥20%): No CAC needed; treat with statin regardless 2
Step 3: Apply CAC Results to Treatment
- CAC = 0: No statin (exceptions: diabetes, family history, smoking) 1
- CAC 1-99: Statin favored if age >55 1
- CAC ≥100: Initiate statin 1
- CAC ≥400: High-intensity statin + aspirin 1, 3
Important Clinical Nuances
Numbers Needed to Treat
The prognostic power of CAC is substantial: 5-year NNT to prevent one ASCVD event is 154 for CAC = 0 versus 30 for CAC ≥100, demonstrating the efficiency of CAC-guided therapy 2
Younger Patients (Age 40-45)
Traditional risk calculators may underestimate risk in younger patients. CAC may have benefit in select younger patients with risk factors (smoking, hyperglycemia, hyperlipidemia, hypertension), as 34% of adults aged 30-49 have CAC >0, with 7.2% having CAC >100 and 10-fold higher mortality 2
Radiation Exposure
Modern dose-reduction strategies have lowered CAC radiation dose to levels comparable to mammography 2
Guideline Consensus (2023)
The ACC/AHA 2019 guidelines provide Class IIa recommendation (Level of Evidence B-NR) for CAC in intermediate-risk adults when preventive intervention decisions remain uncertain 2. The 2017 SCCT expert consensus similarly supports CAC as appropriate for asymptomatic adults aged 40-75 with borderline to intermediate risk 2. The 2021 ESC Prevention Guidelines give Class IIb recommendation for CAC to improve risk classification around treatment thresholds 1.
Common Pitfall to Avoid
Never use CAC to exclude CAD in symptomatic patients. Up to 38% of symptomatic patients with CAC = 0 have obstructive disease, and 20% of occluded vessels have no calcium 2. In symptomatic patients, proceed directly to functional testing or coronary CT angiography.